A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function DREAMM13

What's the purpose of this trial?

This is a phase 1 study evaluating the safety, dosage and tolerability of belantamab mafodotin in participants with relapsed or refractory multiple myeloma with both normal and impaired liver function.

This trial is currently open and accepting patients.

What will happen during the trial?

This trial plans to enroll approximately 24 participants and will be conducted in two different parts:


  • Part 1 will test the safety and determine the best dose of belantamab mafodotin to use in Part 2 and will enroll participants into one of two groups:
    • Group 1 (Normal Liver Function)
    • Group 2 (Moderate Liver Impairment)


  • Part 2 will be conducted with participants who have severe liver impairment and will be enroll into one group:
    • Group 3 (Severe Liver Impairment)

This trial is organized into 21 day cycles. Participants will receive belantamab mafodotin intravenously on day 1 of each cycle.

Patients may not wear contact lenses while participating in this trial.

All participants in this study will need to have their eyes examined to monitor for potential side effects. Patients will need to see an eye specialist before they receive their first dose of belantamab mafodotin, and before each dose for the next four cycles. If you don’t develop eye side effects, eye exam frequency may be reduced to every 6 months at the discretion of the eye specialist.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • Patients must have a diagnosis of multiple myeloma.
  • Patients must have failed at least two prior lines of therapy, including an immunomodulatory drug (e.g.,lenalidomide or pomalidomide), proteasome inhibitor (e.g., bortezomib, ixazomib or carfilzomib)
  • Patients must have undergone an autologous stem cell transplant (or not be eligible to receive a transplant).
  • Patients must have adequate bone marrow, kidney and cardiac function as described by the study parameters.
  • Patients must not have had a prior allogeneic stem cell transplant.
  • Patients must not have previously received belantamab mafodotin.
  • Patients must not have evidence of active internal bleeding.

Additional Trial Information

Phase 1

Enrollment: 28 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


University of Arizona Cancer Center

Tucson, AZ

Open and Accepting


Beverly Hills Cancer Center

Beverly Hills, CA

Open and Accepting


Cancer Specialists of North Florida

Fleming Island, FL

Not Yet Accepting


Loyola University Medical Center Cardinal Bernardin Cancer Center

Maywood, IL

Not Yet Accepting


Cancer Center of Kansas (Heritage Plaza)

Wichita, KS

Open and Accepting


New Jersey


UPMC Hillman Cancer Center University of Pittsburgh Medical Center (UPMC)

Pittsburgh, PA

Open and Accepting



Baylor Charles A. Sammons Cancer Center Baylor Scott & White Health

Dallas, TX

Not Yet Accepting

Joe Arrington Cancer Research and Treatment Center Covenant Health

Lubbock, TX

Not Yet Accepting


Aurora St. Luke's Medical Center

Milwaukee, WI

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with GlaxoSmithKline to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors